CTOs on the Move

Cardiff Oncology

www.cardiffoncology.com

 
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cardiff Oncology raised $13.5M on 06/16/2020

Similar Companies

Argonaut Manufacturing Services

Argonaut Manufacturing Services provides contract manufacturing for pharmaceutical, diagnostics and life science organizations.

Nanosphere

Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its name.

Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body`s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune`s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 150 employees and is located in Oxfordshire, UK and Philadelphia, USA.

ABR--Affinity BioReagents

ABR--Affinity BioReagents is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Induchem Usa

Induchem Usa is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.